Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor

Journal of the European Academy of Dermatology and Venereology

Volumn 31, Issue 8, 2017, Pages e349-e350

  Kwon, C W ^a   Land, A S ^a   Smoller, B R ^a   Scott, G ^a   Beck, L A ^a   Mercurio, M G ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; NIVOLUMAB; PREDNISONE; TRIAMCINOLONE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ADVERSE OUTCOME; BULLOUS PEMPHIGOID; CASE REPORT; CLINICAL FEATURE; DERMOEPIDERMAL JUNCTION; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; KIDNEY METASTASIS; LETTER; MALE; MIDDLE AGED; PRIORITY JOURNAL; RASH; SKIN BIOPSY; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED;

ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; HUMANS; MALE; MIDDLE AGED; NIVOLUMAB; PEMPHIGOID, BULLOUS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85015185608     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.14143     Document Type: Letter

References (7)

1. Naidoo J, Schindler K, Querfeld C et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res 2016; 4: 383–389.
2. Jour G, Glitza IC, Ellis RM et al. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J Cutan Pathol 2016; 43: 688–696.
3. Damsky W, Kole L, Tomayko MM. Development of bullous pemphigoid during nivolumab therapy. JAAD Case Rep 2016; 2: 442–444.
4. Hwang SJ, Carlos G, Chou S, Wakade D, Carlino MS, Fernandez-Penas P. Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies. Melanoma Res 2016; 26: 413–416.
5. Parakh S, Nguyen R, Opie JM, Andrews MC. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma. Australas J Dermatol 2016. DOI: 10.1111/ajd.12488 [Epub ahead of print].
6. Mochel MC, Ming ME, Imadojemu S et al. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma. J Cutan Pathol 2016; 43: 787–791.
7. Fairley JA, Heintz PW, Neuburg M et al. Expression pattern of the bullous pemphigoid-180 antigen in normal and neoplastic epithelia. Br J Dermatol 1995; 133: 385–391.